After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.
More from Imaging Technology News
SenseTime Receives CE Mark for SenseCare-Chest DR Pro Diagnostic Software
Source Node: 808194
Time Stamp: Apr 14, 2021
BLOG: Cloud-Based Imaging Platform Streamlines Workflows, Ensures Data De-Identification and Improves Collaboration in Clinical Trials
Source Node: 846147
Time Stamp: May 3, 2021
FDA Authorizes Marketing of First Device that Uses AI to Help Detect Potential Signs of Colon Cancer
Source Node: 808198
Time Stamp: Apr 12, 2021
Canon Medical Expands AI-Based Image Reconstruction Technology
Source Node: 846149
Time Stamp: Apr 30, 2021
BLOG: Emerging AI Technologies Provide Value Throughout the Patient Journey
Source Node: 808196
Time Stamp: Apr 13, 2021
FDA Clears for ProFound AI Version 3.0 for 3D Mammography
Source Node: 769320
Time Stamp: Mar 23, 2021